Translated with AI
The Ministry of Health and Social Protection of the Republic of Tajikistan has denied reports circulating on social media about schoolchildren in the Farkhor district allegedly being hospitalized after taking the drug Albendazole. This was reported by the press service of the Ministry of Health and Social Protection of the Republic of Tajikistan.
The department reported that audio and video recordings are being circulated in several WhatsApp groups in which a woman claims that several students were hospitalized in serious condition after taking pills given by medical workers.
However, according to the ministry, healthcare specialists in the Farkhor district confirmed that not a single citizen had contacted a medical facility after taking the drug.
It is noted that the distribution of Albendazole among children and adolescents aged 7 to 14 continues in the district's educational institutions as prescribed. No side effects have been reported among students after administration.
The ministry also reported that the video had been analyzed. It was determined that the recording was made not in the Farkhor district, but in the Mir Said Ali Hamadoni district. The video features Farishta Todzhova, born in 2015, a resident of the Dashtigulu jamoat, in the village of Tagnob.
According to doctors, the worsening of her condition is not related to taking Albendazole. It is noted that the girl has been diagnosed with type 1 diabetes, the main factor in the development of which is heredity.
In this regard, the Ministry of Health called on citizens not to trust unfounded rumors regarding medical services.
It is noted that comprehensive deworming is being carried out within the framework of the implementation of the “Strategy for the Protection of Population Health in the Republic of Tajikistan for the Period up to 2030” and the order of the Ministry dated April 6–11, 2026.
From April 6 to 11, a preventive campaign using the drug "Albendazole, 400 mg" is being carried out in cities and districts of the republic among children aged 7 to 14 years in order to reduce the prevalence of helminthic diseases.
